Effective Trading In Our Markets. Learn, then Earn Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Effective Trading In Our Markets. Learn, then Earn

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jerry Olson who wrote (1305)	8/8/2002 3:15:49 PM
From: Frederick Langford	Read Replies (1) of 1854

Time Is Right For Genomics, Says UBS 08 Aug (Dow Jones) UBS Warburg analyst Meirav Chovav wants her voice heard in the market, starting her day by initiating rating on the genomics sector. Notes most genomics companies have shifted their businesses from leveraging technology platforms toward drug development, which remains a difficult and unpredictable process. Therefore, she advocates that investors maintain a long-term view when investing in the genomics sector. On the other hand, considering the sector's current depressed valuations, Chovav believes current market conditions represent opportunities, albeit high-risk ones, to invest selectively in quality genomics companies with prospects for future commercial success. Initiates rating on Millennium Pharmaceuticals (MLNM), Human Genome Sciences (HGSI), Vertex Pharmaceuticals (VRTX) and Myriad Genetics (MYGN) all at buy. Meantime, starts rating on Lexicon Genetics (LEXG) at buy, while Celera Genomics (CRA) and Incyte Genomics (INCY) at hold, which are in earlier stages of drug development. (WRL)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next